TKNO Q3 2021 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$135M

Q3 2021 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$9M+4.5% YoY

Gross Profit

$4M45.4% margin

Operating Income

-$4M-41.4% margin

Net Income

-$3M-34.6% margin

EPS (Diluted)

$-0.12

QoQ Revenue Growth

+13.0%

Cash Flow

Operating Cash Flow

-$5M

Free Cash Flow

-$9M

Stock-Based Comp.

$442,000

Balance Sheet

Total Assets

$169M

Total Liabilities

$23M

Stockholders' Equity

$146M

Cash & Equivalents

$98M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$9M	+4.5%
Gross Profit	$4M	$5M	-16.2%
Operating Income	-$4M	$2M	-280.7%
Net Income	-$3M	$2M	-312.1%

Revenue Segments

Lab Essentials

$7M77%

Clinical Solutions

$2M18%

Other Product

$434,0005%

Sample Transport

$73,0001%

Geographic Segments

UNITED STATES

$9M97%

Non-US

$278,0003%